G&A at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s G&A?
- Kyverna Therapeutics, Inc. (KYTX) reported G&A of $11.29M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s G&A changed year-over-year?
- Kyverna Therapeutics, Inc.'s G&A increased by 13.2% year-over-year, from $9.98M to $11.29M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s G&A has grown at a 70.1% compound annual growth rate (CAGR), from $12.48M to $36.11M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.